Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function by Vannini, E et al.
Original Citation:
Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron
structure and function
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3286968 since:
10.1093/neuonc/now114
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
Electrophysiology of glioma: a Rho GTPase-activating protein reduces
tumor growth and spares neuron structure and function
Eleonora Vannini, Francesco Olimpico, Silvia Middei, Martine Ammassari-Teule, Erik L. de Graaf, Liam McDonnell,
Gudula Schmidt, Alessia Fabbri, Carla Fiorentini, Laura Baroncelli, Mario Costa, and Matteo Caleo
CNR Neuroscience Institute, Pisa, Italy (E.V., F.O., L.B., M.C., Mat.C.); CNR Cellular Biology and Neurobiology Institute, Rome, Italy
(S.M., M.A.-T.); Fondazione Pisana per la Scienza, Mass Spectrometry and Proteomics, Pisa, Italy (E.L.d.G., L.M.); Institut fu¨r
Experimentelle und Klinische Pharmakologie und Toxikologie, Freiburg, Germany (G.S.); Istituto Superiore di Sanita`, Rome,
Italy (A.F., C.F.); Scuola Normale Superiore, Pisa, Italy (M.C., Mat.C.)
Corresponding Author: Matteo Caleo, PhD, CNR Neuroscience Institute, via G. Moruzzi 1, Pisa 56124, Italy (caleo@in.cnr.it).
Background. Glioblastomas are the most aggressive type of brain tumor. A successful treatment should aim at halting tumor
growth and protecting neuronal cells to prevent functional deficits and cognitive deterioration. Here, we exploited a Rho
GTPase-activating bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1), to interfere with glioma cell growth in vitro and
vivo. We also investigated whether this toxin spares neuron structure and function in peritumoral areas.
Methods.We performed a microarray transcriptomic and in-depth proteomic analysis to characterize the molecular changes trig-
gered by CNF1 in glioma cells. We also examined tumor cell senescence and growth in vehicle- and CNF1-treated glioma-bearing
mice. Electrophysiological and morphological techniques were used to investigate neuronal alterations in peritumoral cortical
areas.
Results. Administration of CNF1 triggered molecular and morphological hallmarks of senescence in mouse and human glioma
cells in vitro. CNF1 treatment in vivo induced glioma cell senescence and potently reduced tumor volumes. In peritumoral
areas of glioma-bearing mice, neurons showed a shrunken dendritic arbor and severe functional alterations such as increased
spontaneous activity and reduced visual responsiveness. CNF1 treatment enhanced dendritic length and improved several phys-
iological properties of pyramidal neurons, demonstrating functional preservation of the cortical network.
Conclusions. Our findings demonstrate that CNF1 reduces glioma volume while at the same time maintaining the physiological
and structural properties of peritumoral neurons. These data indicate a promising strategy for the development of more effective
antiglioma therapies.
Keywords: cytotoxic necrotizing factor 1, dendritic structure, evoked potentials, senescence, visual cortex.
Glioblastoma (GBM) is an aggressive form of brain tumor
typically associated with a poor prognosis.1 Survival rates and
quality of life of the patients have scarcely improved in the
last years. Thus, it is urgent to find innovative approaches for
GBM treatment. The development of novel therapies requires
a better understanding of the biology of glioma cells and
their interactions with resident brain cells. In particular, glioma
cells are known to release high amounts of glutamate, leading
to overexcitation of peritumoral neurons and epileptic sei-
zures,2 with consequent neuronal death by excitotoxicity. This
neuronal loss may facilitate glioma invasion3 and underlie cog-
nitive impairments in patients.4,5 A successful brain tumor
treatment should therefore aim at protecting neuronal cells
to prevent functional deficits and cognitive deterioration,
which have a strong impact on patients’ quality of life.
Currently, very little information is available about the func-
tional status of peritumoral tissue at the border of the glioma
mass. Previous studies have reported accumulation of gluta-
mate6 as well as excitatory actions of gamma-aminobutyric
acid (GABA),7 whichmay explain the occurrence of epileptic sei-
zures. However, how tumor growth reverberates on the activity
of single cells and the function of neuronal networks remain
completely uncharted. Gathering this information is critical
from at least 2 points of view. First, neuronal activity in peritu-
moral areas can potently influence brain tumor growth via
the release of glioma mitogens.8 Second, novel antiglioma
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therapies should ideally aim at blocking tumor growth without
noxious side effects on neurons. Indeed, an important ad-
vancement in preclinical tests of antineoplastic drugs would
be the incorporation of physiological assays measuring neuro-
nal function at the glioma border.
In this manuscript, we have exploited glioma cell transplan-
tation into the mouse visual cortex to obtain quantitative mea-
sures of neuronal responsiveness at the border of the tumor.
The visual cortex is a suitable model system, since it is particu-
larly easy to identify alterations in the response to physiological
stimuli.9
To halt glioma growth and preserve peritumoral regions, we
used a Rho GTPase-activating protein, the bacterial toxin cyto-
toxic necrotizing factor 1 (CNF1). This toxin induces multinu-
cleation of glioma cells10 while exerting a “plasticizing” effect
on neurons, with enhanced dendritic branching and long-term
potentiation.11,12 CNF1 enters cells close to the site of delivery
and catalyzes the deamidation of a single glutamine residue in
Rho GTPases (Rho, Rac, and Cdc42), thus impairing hydrolysis of
guanosine triphosphate (GTP) and leading to their permanent
activation.13,14 This leads to a double effect: (i) actin stabiliza-
tion, blockade of cytodieresis, and eventually cell death in
proliferating glioma cells10 and (ii) promotion of neuron health
and plasticity.12 We therefore tested whether CNF1 treatment
may reduce tumor growth and at the same time preserve
the functionality and structure of the neurons surrounding
the glioma.
Materials and Methods
For detailed experimental procedures, see the Supplementary
Material.
Cell Cultures
GL261 cells were grown according to American Type Culture
Collection protocols. Primary human glioblastoma cells were col-
lected from 2 subjects as described in our previous publication.10
The study was approved by the Human Ethics Committee of the
University of Pisa and Pisa Hospital. Cells were treated with CNF1
(3 nM) and incubated for 48 h before b-galactosidase measure-
ments. The percentage of positive cells was determined after
counting 3 random fields.
Microarray Analysis and Real-Time PCR
After RNA extraction, gene expression profiling was performed
using a standard 2-color protocol by Agilent. Complementary
RNAwas hybridized to an Agilent 4×44k whole mouse genome
microarray (G4122F) using the facility at the European Brain Re-
search Institute (Rome, Italy). Quantitative real-time (RT) PCR
reactions were performed using the SYBR PCR Mastermix (Ap-
plied Biosystems) on a StepOnePlus Real-Time PCR System (Ap-
plied Biosystems).
Proteomics Analysis
The proteomics experiment was performed as described be-
fore.15 Briefly, cells were lysed in a urea-based lysis buffer
and digested with Lys-C and trypsin. Peptide labeling was
performed with Tandem Mass Tag 6-plex labeling, and
fractionation was performed using high pH reverse phase
fractionation on a BRAVO AssayMAP (Agilent Technologies).
Nano-scale liquid chromatography–tandem mass spectrom-
etry analysis was performed on a 50 cm Easyspray column
and an Orbitrap Fusion for MS3 analysis (Thermo Fisher Scien-
tific). Data were analyzed using MaxQuant16 and Database for
Annotation, Visualization and Integrated Discovery (DAVID)17
software.
Animals and Tumor Induction
Adult (age .postnatal day 60) C57BL/6J and Thy1-GFP mice
were used. All experimental procedures conformed to the Euro-
pean Communities Council Directive #86/609/EEC and were ap-
proved by the Italian Ministry of Health. To induce glioma
formation, C57BL/6 and Thy1-GFP mice received a stereotaxi-
cally guided injection of 40 000 GL261 cells (20 000 cells/mL
phosphate buffered saline solution) into the visual cortex
(2 mm lateral to the midline and in correspondence with lamb-
da). Five days after injection of GL261 cells (tumor induction),
mice were divided into 2 groups. The first group received
CNF1 injection, the second, named “vehicle,” Tris–HCl buffer in-
jection (glioma control condition).
Immunohistochemistry
Glioma volumes were measured in serial cortical sections using
Stereo Investigator software (MicroBrightField). To quantify
density of glial cells in the peritumoral areas, we used primary
antibodies directed against glial fibrillary acidic protein (GFAP)
(1:500; Dako) and Iba-1 (1:500; Wako).12 Positive cells were
then counted in regions adjacent to the tumor.
Assessment of Senescence In vivo
Coronal sections were stained for senescence-associated
b-galactosidase (SA b-gal) and coverslipped. Images of the
tumor border and surrounding neural tissue were acquired
with a Zeiss microscope and Axiovision software. Mean signal
intensity was measured with Metamorph software.
Electrophysiological In vivo Recordings
Recordings were performed as described previously.9,18 Mice
were anesthetized with urethane (150 mg/mL/kg), and a tung-
sten electrode was inserted into the visual cortex to record vi-
sual evoked potentials (VEPs) and single unit spiking activity.
VEPs were recorded in response to a horizontal square wave
grating of different spatial frequency and contrast. We mea-
sured either the peak-to-trough amplitude of the major nega-
tive component (transient VEPs) or the amplitude of the second
harmonic of the Fourier transform computed from the recorded
signal (steady-state). For spiking activity, the visual stimulus
consisted of a light bar drifting in the central part of the visual
field. Spikes were discriminated from background by a voltage
threshold, as described.9,18 Peak responses were determined
from peristimulus time histograms.
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Neuronal Morphology
To investigate morphological alterations in peritumoral neu-
rons, we transplanted glioma cells into the visual cortex of
Thy1-GFP mice.19 Pyramidal neurons 100–300 mm away from
the tumor borders were 3D reconstructed with Neurolucida
software (MicroBrightField). Total dendritic length and dendritic
branch number were quantified for each reconstructed neuron
with Neurolucida Explorer software (MicroBrightField). For each
neuron, the dendritic tree complexity was quantified using Sholl
analysis.
Statistical Analysis
Differences between 2 groups were assessed with a t-test, or a
Mann–Whitney rank sum test for datasets not normally distrib-
uted. Differences among 3 or more groups were evaluated with
ANOVA followed by either Holm–Sidak or Dunn’s test. For Sholl
analysis and contrast gain curves, we carried out a 2-way re-
peated measures ANOVA.
Results
Molecular Changes Triggered by CNF1 in Glioma Cells
We have previously demonstrated that CNF1 induces multinu-
cleation and eventually death of glioma cells.10 To fully describe
the molecular profile induced by CNF1 in glioma cells, GL261
cells were treated with CNF1 or vehicle followed by microarray
transcriptomic and in-depth proteomic analysis at 48 h
(Fig. 1A–C). The expression profile of 27 122 transcripts and
4246 proteins was analyzed. Using a fold change cutoff of 2,
we found a total of 1711 transcripts that were downregulated,
while another 1318 were upregulated. Due to the very strict
constraints in the proteomic analysis, a lower number of regu-
lated proteins (129 proteins upregulated and 67 downregu-
lated) was reported when compared with the microarray
data. In order to get an overview of CNF1-altered processes/
pathways, we performed functional enrichment analysis on
both the transcriptomics and proteomics, using the bioinfor-
matics tools WebGestalt20,21 and DAVID.17,22 The most signifi-
cantly enriched transcripts (threshold value, P, .05) in the
network were associated with cell cycle/senescence, DNA rep-
lication, and mitogen-activated protein kinase signaling
(Fig. 1A). In CNF1-treated samples, we found a significant
downregulation of receptors for growth factors (such as epider-
mal growth factor [EGF] and platelet-derived growth factor
[PDGF]) involved in glioma progression (Fig. 1B). There was
also a consistent and marked upregulation of senescence-
associated genes such as Cdkn1a/p21 and uridine phosphory-
lase 1 (Upp1) (Fig. 1B). Accordingly, the proteomic screening
showed a strong upregulation of p21 and Upp1 protein levels
(Fig. 1C). Western blot was performed to address some of the
intracellular signaling pathways highlighted by the microarray
analysis. We found that CNF1 treatment induced a clear reduc-
tion of phosphorylated Erk while the fraction of phosphorylated
Akt was increased (Supplementary Fig. 1), consistent with a
previous report.23
We next compared the effects of CNF1 in murine GL261 and
human glioma cells (U87 glioma cell line and patient-derived
GBM cell cultures). In a first set of experiments, we used
quantitative RT-PCR to examine the expression of genes related
to senescence. In GL261 cells, we found that the expression of
senescence-associated genes p16 and p21 was upregulated,
while the Forkhead box protein G1 gene,24 a negative transcrip-
tional regulator of p21, was strongly downregulated (t-test, P,
.05; Fig. 1D). A similar upregulation of p21 was detected in
CNF1-treated U87 and patient-derived cells (t-test, P, .05;
Fig. 1E and F). Second, we examined the senescence phenotype
at the morphological level by performing staining for SA b-gal
activity in GL261 cells and human glioma cells treated with
CNF1 (3 nM) or vehicle for 48 h. GL261 cells exposed to CNF1
exhibited a significant increase in SA b-gal activity compared
with control cells (t-test, P, .01; Fig. 2A). As expected by the
upregulation of p21, U87 and GBM-derived cells also stained
strongly positive for SA b-gal following CNF1 treatment
(t-test, P, .01; Fig. 2B and C). Altogether, these data indicate
that CNF1 triggers molecular and morphological hallmarks of
senescence in GL261 and human glioma cells, including
patient-derived cells.
CNF1 Induces Senescence of Glioma Cells and Reduces
Tumoral Volume In vivo
To evaluate the effects of CNF1 on glioma cells in vivo, GL261
cells were transplanted into the primary visual cortex of adult
mice, and CNF1 (or vehicle) was delivered into the transplant
site 5 days later. The neuroanatomical analysis was performed
at day 21. We first stained coronal sections for SA b-gal activity
to check activation of the senescence pathway following CNF1
treatment in vivo. A robust staining for SA b-gal was apparent in
CNF1- but not vehicle-treated glioma-bearing animals, espe-
cially at the border of the tumormass (Fig. 2D and E). The quan-
titative analysis demonstrated a significant difference in SA
b-gal labeling between CNF1 and vehicle treatment (t-test,
P, .001; Fig. 2F).
A stereological analysis was also performed to quantify the
tumoral volume in vehicle- and CNF1-treated mice. We found
that CNF1-treated animals exhibited markedly reduced tumor
volumes compared with controls (Mann–Whitney rank sum
test, P, .05; Fig. 3A and B). To investigate whether CNF1
could affect recruitment of astroglial and microglial cells at
the border of the tumor, we performed immunostainings for
Iba-1 and GFAP 21 days following glioma cell transplant
(Fig. 3B). GFAP-positive astrocytes in peritumoral borders have
typical thick processes that allow their identification with re-
spect to GFAP-stained glioma cells within the tumor mass
(Fig. 3B, insets). The quantitative analysis demonstrated an in-
creased density of astrocytes and microglia in CNF1-treated
mice (Mann–Whitney rank sum test, P, .001; Fig. 3C, D), indi-
cating that CNF1 treatment recruits glial cells in proximity to
the tumor.
Sparing of Neuronal Responses in CNF1-Treated
Glioma-Bearing Mice
To evaluate functional changes induced by GL261 injection, we
performed extracellular recordings of local field potentials and
spiking activity from the primary visual cortex of anesthetized
mice 21 days after glioma cell inoculation. A schematic of the
transplant and recording sites is provided in Supplementary
Vannini et al.: Sparing of neuronal function in glioma
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Fig. 2A. In keeping with the neuroanatomical data, we found
different extents of tumor growth in vehicle- and CNF1-treated
mice prepared for electrophysiological experiments. Indeed,
more than 40% of vehicle-treated glioma-bearing mice could
not be recorded, since the tumoral mass had completely cov-
ered the cortical surface in correspondence with the planned
recording sites (Supplementary Fig. 2B). In contrast, this oc-
curred in only about 14% of glioma-bearing mice treated
with CNF1 (z-test, P, .05).
We initially used VEP recordings to compare visual respon-
siveness of naı¨ve animals and glioma-bearing mice treated
with either CNF1 or vehicle. Representative VEP waveforms
are shown in Fig. 4A. We found a significant reduction of abso-
lute VEP amplitudes in vehicle-treated glioma mice (1-way
ANOVA followed by Holm–Sidak test, P, .05; Fig. 4A). This re-
duction was completely counteracted by CNF1 treatment
(Fig. 4A). Latency of visual drive (i.e., of the major positive VEP
peak) was in the order of 100 ms and was unaffected by exper-
imental treatment (1-way ANOVA, P¼ .175; Fig. 4B). We then
evaluated visual responses at different contrast levels and
found that in vehicle-treated glioma-bearing mice, VEP ampli-
tudes were scaled down across a range of contrasts compared
Fig. 1. Transcriptomic and proteomic profile of CNF1-treated glioma cells. Genes and proteins differentially expressed in CNF1- vs vehicle-treated
glioma cells, 48 h after treatment. (A) The most significant gene categories are displayed at the top of the graph downward (P-value, red line) and
gene numbers are arranged horizontally by the length of the bars (gene counts, blue bars). (B) Microarray heat map of selected genes differentially
expressed at 48 h in CNF1-treated GL261 cells. Gene expression is represented by the intensity of colors (green: lowest expression; red: higher
expression). Note significant upregulation of senescence-associated genes such as p21 and Upp1, and downregulation of several growth factor
receptors (EGF and PDGF receptors) in CNF1-treated samples. (C) Volcano plot of all quantified proteins (4246 total). The triplicate average ratio
CNF1 vs control was plotted against their t-test statistical log P-values. Significantly regulated proteins (total of 196 proteins, permutation
corrected false discovery rate, 0.001) were colored in red and green for up- and downregulation, respectively. (D) Quantitative RT-PCRs
showing the relative expressions of the senescence markers p21 (Cdkn1a, cyclin-dependent kinase inhibitor 1) and p16 (Cdkn2a,
cyclin-dependent kinase inhibitor 2), and the negative p21 regulator FoxG1 (Forkhead box protein G1) in GL261 cells. (E, F) Increased
expression of p21 in human glioma cells: U87 cell line (E) and patient-derived GBM cell cultures (F). Data are mean+SEM. *P, .05, **P, .01,
***P, .001 (t-test).
Vannini et al.: Sparing of neuronal function in glioma
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with naı¨ve and CNF1-treated mice (2-way repeated measures
ANOVA followed by Holm–Sidak test, P, .05; Fig. 4C). Impor-
tantly, CNF1-treated animals showed a normal contrast gain
function, with VEP amplitudes that were superimposable to
those of naı¨ve mice (P. .05; Fig. 4C).
To further probe functional changes induced by GL261 cell
injection and the maintenance of neuronal responses in the
peritumoral area of CNF1-treated animals, we also recorded ex-
tracellular spiking activity. Analysis of spontaneous discharges
(i.e., without visual stimuli) revealed a profound enhancement
of baseline firing in both groups of glioma-bearing mice (1-way
ANOVA on ranks followed by Dunn’s test, P, .01; Fig. 5A), indi-
cating hyperexcitability of peritumoral regions. We then quanti-
fied the responsiveness of cortical neurons to visual stimulation
as the peak-to-baseline ratio, that is, the peak discharge evoked
by visual stimulation divided by spontaneous activity.9,18 We
found a profound depression of responsivity in vehicle-infused
glioma-bearing mice compared with naı¨ve and CNF1-treated
animals (1-way ANOVA on ranks followed by Dunn’s test, P, .01
for both comparisons; Fig. 5B). Visual responsiveness in
CNF1-treated mice was intermediate between vehicle-treated
glioma-bearing and naı¨ve mice (P, .01; Fig. 5B). To investigate
whether the dampened peak-to-baseline ratio in neurons from
glioma-bearing mice may be ascribed to a reduced reliability
of visual responses, we counted failures (the percentage of
stimulus presentations unable to modify spontaneous activity)
in all experimental groups.9 We detected an abnormally high
failure rate (about 30%) in control glioma-bearing mice, which
was completely recovered by CNF1 delivery (1-way ANOVA fol-
lowed by Holm–Sidak test, vehicle vs naı¨ve and CNF1, P, .05;
CNF1 vs naı¨ve, P¼ .73; Fig. 5C). Moreover, vehicle-infused
glioma-bearing mice showed an increase in neuronal receptive
field size in comparison with naı¨ve and CNF1-treated groups
(1-way ANOVA on ranks followed by Dunn’s test, P¼ .011;
Fig. 5D).
To define more precisely how CNF1 treatment per se affects
normal cortical function, we conducted control experiments to
measure neuronal properties in CNF1-injected naı¨ve mice (n¼
4). Consistent with our previous report in rats,12 we found no
alterations in cell physiology (t-test and Mann–Whitney rank
sum test, P. .05; Supplementary Fig. 3). We noted a small,
nonsignificant increase in spontaneous activity (Supplementary
Fig. 2. CNF1 induces senescence of glioma cells. (A–C) Percentage of SA b-gal positive GL261 (A), U87 (B), and GBM-derived glioma cells (C) 48 h
after CNF1 treatment. Data are mean+SEM. **P, .01 (t-test). (D, E) Representative coronal brain sections from glioma-bearing mice treated with
either vehicle (D) or CNF1 (E). Note very intense SA b-gal staining (blue) in the CNF1-treated animal. For both images, the glioma mass is on the
right while the intact peritumoral cortex is on the left. Scale bar¼ 200 mm. (F) Quantification of SA b-gal staining in vehicle- and CNF1-treatedmice.
The horizontal lines in the box denote the 25th, 50th, and 75th percentile values. The error bars denote the 5th and 95th percentile values, and the
square symbol represents the mean of the column of data. SA b-gal staining is more intense in CNF1-treated mice (Mann–Whitney rank sum test,
***P, .001).
Vannini et al.: Sparing of neuronal function in glioma
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Fig. 3A) which may be linked to the enhanced density of den-
dritic spines in CNF1-treated neurons.12
Morphological Preservation of Peritumoral Neurons
by CNF1
To investigate alterations of neuronal structure in peritumoral
areas, we transplanted GL261 cells in Thy1-GFP mice express-
ing GFP in a subset of layer V pyramidal neurons (Fig. 6A). Two
weeks after transplant, we reconstructed GFP-stained neurons
in visual cortex (Fig. 6B) and quantified total dendritic length
and complexity in peritumoral neurons (cell somas were locat-
ed 100–300 mm from the tumor border). Overall, neurons in
peritumoral regions had a shrunken appearance and reduced
branching (Fig. 6B). Total dendritic length was strongly reduced
in vehicle-infused glioma-bearing mice, and CNF1 treatment
partially recovered this phenotype (Mann–Whitney rank sum
test, P, .05; Fig. 6C). We also examined dendrite complexity
by Sholl analysis. The number of intersections between den-
drites and Sholl circles was significantly reduced in vehicle-
treated glioma-bearing mice (Fig. 6D). Dendritic branching
was significantly preserved by CNF1 at distances ≤30 mm
from the cell soma (2-way repeated measures ANOVA followed
by Holm–Sidak test, P, .05; Fig. 6D). Altogether, these data
demonstrate that CNF1 treatment protects the dendritic archi-
tecture of peritumoral neurons, indicating a morphological cor-
relate of the maintained visual responsivity.
Discussion
We previously demonstrated that intracerebral CNF1 delivery
increases survival of glioma-bearing mice,10 but the molecular
Fig. 3. CNF1 reduces tumor volume in vivo. (A) Reduced tumoral volume in CNF1-treated animals. Volumes were measured 21 d after GL261
injection in vehicle- (Veh, n¼ 10) and CNF1-treated animals (n¼ 17; Mann–Whitney rank sum test, P, .05). Horizontal lines in the box chart
denote the 25th, 50th, and 75th percentile values. Error bars denote the 5th and 95th percentile values, while the square indicates the mean
of the data. *P, .05. (B) Representative Hoechst-stained coronal sections through the visual cortex from mice inoculated with GL261 cells and
treated either with vehicle (top) or CNF1 (bottom). Note the bigger tumoral mass in the vehicle mouse. Dorsal is up and lateral is to the right. The
box on the left shows GFAP labeling within the tumor mass, while the boxes at right show GFAP-positive astrocytes and Iba-1–stained cells. Scale
bar¼ 500 mm (10 mm for insets). (C) Quantification of GFAP-positive cells in the visual cortex surrounding the tumoral mass. Number of cells per
boxes counted in vehicle- (Veh, gray box chart, number of boxes counted¼ 65) and CNF1-treatedmice (blue box chart, number of boxes counted¼
135; Mann–Whitney rank sum test, ***P, .001). (D) Quantification of Iba-1–positive cells in the visual cortex surrounding the tumoral mass.
Number of cells per boxes counted in vehicle- (Veh, gray box chart, number of boxes counted¼ 67) and CNF1-treated mice (blue box chart,
number of boxes counted¼ 120; Mann2Whitney rank sum test, ***P, .001).
Vannini et al.: Sparing of neuronal function in glioma
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pathways set in motion by CNF1 remain only partly understood.
To characterize in detail the effect of CNF1 on glioma cells, we
carried out a full transcriptomic and proteomic analysis. These
data are important for the definition of CNF1 mechanisms of
action.25–28 First, we found a significant downregulation of sev-
eral trophic factors and receptors involved in glioma progres-
sion, which may be linked to the antitumoral properties of
CNF1. Second, we found evidence for activation of the senes-
cence pathway in CNF1-treated cells, with activation of SA
b-gal. SA b-gal activity is a widely used and reliable biomarker
in studies of cellular senescence in culture and in vivo, even if it
is not completely specific.29 The activation of senescence was
supported by enhanced expression of p21/p16 and was consis-
tently observed in murine and human cell lines. To link these
data in cell cultures with the in vivo condition, we evaluated
staining for SA b-gal in tumors treated with CNF1. Consistently,
the results indicated a robust and massive induction of cellular
senescence (see Fig. 2D–F). These senescence-promoting ef-
fects are likely one of the key mechanisms involved in the re-
duced tumor growth observed following intracerebral CNF1
treatment (see Fig. 3A).
In addition, we used glioma cell injections into the mouse
visual cortex to precisely characterize functional and structural
alterations in pyramidal neurons located in peritumoral areas.
One of the most dramatic physiological alterations detected in
our recordings was the increased baseline firing of cortical neu-
rons, which may represent the cellular substrate underlying en-
hanced propensity to spontaneous seizures in peritumoral
areas.7,30 Higher firing rates may depend on glutamate release
from the tumor2 as well as on alterations of chloride homeo-
stasis in neurons, resulting in a net depolarizing efflux of
chloride-negative ions upon GABA-A receptor opening.7,31
Changes in the excitation/inhibition ratio may also be at the
basis of the increased receptive field size of cortical neurons.32
Our data indicate reduced visual responses in the peritumoral
regions, as shown by a dampened VEP amplitude. This may
be due to 2 distinct, nonmutually exclusive possibilities: a dam-
age to afferent thalamocortical fibers secondary to tumor
growth in the white matter, or a reduced recruitment of cortical
neurons because of alterations in intracortical connectivity. Vi-
sually evoked firing activity was also downregulated, and this
was linked to a higher incidence of failures in responding to
the visual stimuli. It is possible that the higher baseline activity
occludes response to physiological stimuli, as we recently ob-
served in the visual cortex rendered epileptic by tetanus neuro-
toxin.9 Altogether, these data provide a set of quantitative
parameters to measure dysfunction in peritumoral regions dur-
ing glioma growth and to assess the effect of neuroprotective
strategies. These parameters can also be employed to measure
precisely the impact of radiotherapy, chemotherapy, and anti-
epileptic drugs on neuronal function in glioma-bearing animals.
The inclusion of physiological endpoints in preclinical glioma
studies is highly warranted in order to deepen our understand-
ing and treatment of neuronal dysfunction related to cancer
and cancer therapies.
Importantly, CNF1 injection appears to rescue, at least in
part, the pathological phenotypes of peritumoral neurons. In
our electrophysiological experiments, we found that CNF1 pre-
serves VEP amplitudes, enhances the reliability of visually
evoked discharges, and maintains a normal contrast response
Fig. 4. Preservation of VEP responses in CNF1-treated glioma-bearing
mice. (A) Transient VEP amplitude in naı¨ve, vehicle (Veh), and CNF1
glioma-bearing mice. Representative waveforms from each group are
shown on top. Responses in vehicle-treated mice (n¼ 7) are
consistently lower compared with CNF1-treated glioma mice (n¼ 6)
and naı¨ve animals (n¼ 6; 1-way ANOVA followed by Holm–Sidak test,
P, .05). Data are mean+SEM. *P, .05. (B) Latency of transient VEPs in
naı¨ve, vehicle-, and CNF1-injected glioma-bearing mice. There are no
statistical differences among groups (1-way ANOVA, P¼ .175). Data
are mean+SEM. (C) Amplitude of steady-state VEPs is plotted as a
function of variable contrast (10%, 20%, 30%, 90%) in control and
GL261-injected mice. Noise level (dotted line) represents the response
to a blank stimulus (0% contrast). VEP responses are strongly reduced
in vehicle glioma-bearing mice with respect to both naı¨ve and
CNF1-infused animals (2-way repeated measures ANOVA followed by
Holm–Sidak test). Naı¨ve, n¼ 6; vehicle-treated glioma-bearing mice,
n¼ 7; CNF1-treated glioma-bearing mice, n¼ 6. Data are mean+
SEM. *P, .05, **P, .01.
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curve and receptive field size in cortical neurons. It is worth not-
ing that the GL261 model represents a rather focal glioma
model; in more diffuse/infiltrating tumors with less distinct bor-
ders, the electrophysiological effects of the tumor and the im-
pact of CNF1 therapy may be different. The physiological
differences in vehicle- versus CNF1-treated glioma-bearing
mice cannot be ascribed to the reduced tumor growth, that
is, to the sampling of cortical regions more distant from the
tumor border in CNF1-injected mice. Indeed, we discarded
more than 40% of vehicle-treated mice (Supplementary
Fig. 2B) and made sure that physiological data were collected
from a subgroup of vehicle- and CNF1-treated animals with
similar tumor volumes (see Supplementary material). In addi-
tion, enhancement of spontaneous activity was noted in both
vehicle- and CNF1-treated mice, likely reflecting similar expo-
sure to glutamate and other neuroexcitants released from
the nearby glioma cells. These data strongly suggest that
CNF1 maintains functional responses via a direct action on
neurons, independently of the reduced tumoral growth. In
keeping with this scenario, CNF1 administration to brain slices
was found to enhance excitatory synaptic transmission and
long-term potentiation.11
At the level of fine neuronal structure, glioma growth po-
tently impacted on the dendritic arbors of peritumoral neurons,
which were dramatically reduced in length and complexity. To
our knowledge, this is the first report of neurite alterations in
glioma. Importantly, CNF1 improved dendritic length and in-
creased dendritic complexity, at least close to the cell soma
(see Fig. 6). This indicates selective preservation of primary den-
drites with concomitant loss of higher-order branches in
CNF1-treated cortical neurons. This morphological rescue is in
line with the improved neuronal responses, indicating that
CNF1 maintains neuron health and function.
In summary, we have shown that CNF1 treatment results in
reduced glioma volumewhile at the same timemaintaining the
physiological and structural properties of peritumoral neurons.
Fig. 5. Sparing of functional properties of cortical units by CNF1 treatment. (A) Spontaneous firing of neurons in naı¨ve (n¼ 11, 164 cells recorded),
vehicle-injected (Veh; n¼ 8, 121 cells recorded), and CNF1-injected (n¼ 9, 111 cells recorded) glioma-bearingmice. Both glioma groups differ from
naı¨ve (ANOVA on ranks, post hoc Dunn’s test, **P, .01). (B) Neuronal responsivity (peak firing evoked by visual stimulation divided by spontaneous
activity) in naı¨ve, vehicle, and CNF1 glioma-bearing mice. Compared with naı¨ve mice, glioma-bearing animals display a lower responsivity which is
partially counteracted by CNF1 (1-way ANOVA on ranks, post hoc Dunn’s test, glioma-bearing vehicle vs CNF1, **P, .01). (C) Percentage of failures
(lack of response to a light bar drifting into the receptive field) of cortical units. Note the higher percentage of failures in vehicle animals with glioma
(1-way ANOVA, post hoc Holm–Sidak test, *P, .05). (D) Box charts showing neuronal receptive field size in naı¨ve animals, and vehicle- and
CNF1-treated glioma-bearing mice. Note the increase in receptive field size for vehicle glioma-bearing mice compared with naı¨ve and
CNF1-treated group (1-way ANOVA on ranks, post hoc Dunn’s test, **P, .01).
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These data therefore suggest a promising strategy for the
development of a more effective antiglioma therapy. Our phys-
iological approach is very relevant, since neuronal activity in the
vicinity of the tumor can influence glioma growth and progres-
sion.8 It is worth noting that tissue preservation per se does not
predict sparing at the functional level.33,34 We introduce here
an electrophysiology-based approach to test the effectiveness
of anticancer therapies by measuring neuronal function and
neuroprotection at the glioma border.
Supplementary Material
Supplementary material is available online at Neuro-Oncology
(http://neuro-oncology.oxfordjournals.org/).
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